GlassScriptPhysician profile
Craig D Astle
NPI 1033119862
$1,888.74
in general payments reported to CMS, 2019-2025
22 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $296 · 2021: $303 · 2022: $424 · 2023: $268 · 2024: $169 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $730.44 | 2019-2025 | Solyx Sis System, Obtryx System - Curved |
| Abbvie INC. | $283.25 | 2019-2023 | Orilissa |
| Ethicon US, LLC | $164.05 | 2022-2025 | Dermabond Prineo, Stratafix, Vistaseal |
| Mayne Pharma Commercial LLC | $90.44 | 2023 | |
| Hologic Sales and Service, LLC | $78.31 | 2021-2025 | Thinprep 2000 Processor, Myosure Tissue Removal Device, Aptima |
| Evofem Biosciences, INC. | $72.49 | 2021-2022 | |
| Biogen, INC. | $66.92 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $56.18 | 2021-2025 | Injectafer |
| Femselect INC. | $46.78 | 2023 | Enplace |
| Becton, Dickinson and Company | $37.86 | 2020-2022 | |
| Medtronic, INC. | $26.21 | 2022 | |
| Coloplast Corp | $24.04 | 2023 | Altis |
| Sumitomo Pharma America, INC. | $23.64 | 2024 | Myfembree |
| Avanos Medical | $23.49 | 2024 | On-Q* Pump and Accessories |
| Eyepoint US, INC. | $22.93 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $22.71 | 2022 | |
| Therapeuticsmd, INC. | $22.27 | 2022 | |
| Exeltis, USA INC. | $20.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.21 | 2021 | |
| Roche Diagnostics Corporation | $19.21 | 2021 | |
| Lupin INC. | $18.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Astle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.